Altimmune Stock Price

-0.44 (-3.46%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Altimmune Inc ALT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.44 -3.46% 12.29 15:42:24
Open Price Low Price High Price Close Price Prev Close
12.48 11.96 12.50 12.73
Bid Price Ask Price Spread News
12.28 12.30 0.02 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
6,840 731,666 $ 12.21 $ 8,930,346 1,509,910 2.88 - 35.10
Last Trade Time Type Quantity Stock Price Currency
15:42:24 34 $ 12.2999 USD

Altimmune Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 456.49M 37.14M 32.26M $ 5.80M $ - -1.52 -7.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Altimmune News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ALT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week13.0713.3211.9612.76800,520-0.78-5.97%
1 Month17.2617.5911.9614.391,199,999-4.97-28.79%
3 Months12.9924.6111.6516.761,644,137-0.70-5.39%
6 Months13.0824.617.8014.091,626,673-0.79-6.04%
1 Year3.5035.102.8815.222,534,8858.79251.14%
3 Years0.8836.250.24510.561,385,65711.411,296.59%
5 Years7.3136.250.24510.251,098,7654.9868.13%

Altimmune Description

Altimmune Inc is a United States-based clinical-stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of liver diseases. The firm's product candidates include NasoVAX, HepTcell, SparVax-L, and NasoShield. It also develops platform technologies such as RespirVec and Densigen. The company generates its revenue from cost plus fee contracts and fixed-price contracts.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.